Skip main navigation

Home > Search Results

Main contents starts here

Search Results

141 - 160 of about 337

Total 337 documents found.

  •  
  • Safety & Health Management Policy
  • Takeda allocates a Safety and Health Officer for every business unit, where all members participate in activities to ensure safety and health in their workplace.
  • Organization of Takeda Pharmaceutical Company Limited 2 0 1 0 . 8 . 1 Board of Corporate Auditors Corporate Auditors Oce of the Corporate Auditors Board of Directors Chairman Corporate Strategy & Planning Department Strategic Product Planning Department Oce of the President & CEO Human Resources Department Finance & Accounting Department Legal Department Corporate Communications Department Global Licensing & Business Development Department Administrative Management Department Pharmaceutical Aairs Auditing Department Global Quality Assurance Department Environment & Safety Department Pharmaceutical Research Division CMC Center Pharmaceutical Development Division Intellectual Property Department Pharmaceutical Production Division Pharmaceutical Marketing Division Division of International Operations (Asia) General Aairs & Personnel Center Accounting Center Consumer Healthcare Company President Management and Operations Committee
  • Takeda Announces Changes in Board Membershipand Management Legal Department June 25, 2009
  • Osaka, Japan, June 25, 2009 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced the election of two new members to its Board of Directors and the appointment of a new Corporate Auditor following its 133rd General Shareholders’ Meeting held today in Osaka and also announced the appointment of a new General Manager, Legal Department. Details of these appointments are as follows:
  • Takeda Announces Completion of Tender Offer for All Outstanding Shares of IDM Pharma, Inc. June 23, 2009
  • OSAKA, JAPAN and NEW YORK, New York, USA, June 23, 2009 – Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) today announced the completion of the tender offer made through Jade Subsidiary Corporation (“Jade”), a wholly owned subsidiary of Takeda America Holdings, Inc., which is a wholly owned subsidiary of Takeda, for all of the outstanding shares of IDM Pharma, Inc. (“IDM”, NASDAQ: IDMI) common stock for US$2.64 per share. The offering period expired at midnight, New York City time, at the end of Monday, June 22, 2009.
  • Amgen, Takeda and Millennium Provide Update on Phase3 Trial of Motesanib in Patients with Non-small Cell Lung Cancer November 20, 2008
  • THOUSAND OAKS, Calif. (Nov. 19, 2008) – Amgen (NASDAQ:AMGN) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study’s independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
  • Transfer of Shares of Sumitomo Chemical Takeda Agro Company, Ltd.from Takeda to Sumitomo Chemical November 1, 2007
  • November 1, 2007, Osaka, Japan --- Takeda Pharmaceutical Company Limited (“Takeda”, President: Yasuchika Hasegawa) announced today that all of Takeda’s shares of Sumitomo Chemical Takeda Agro Company, Ltd. (“SCTA”, President: Shigeki Tashiro) had been transferred to Sumitomo Chemical Co., Ltd. (“Sumitomo”, President: Hiromasa Yonekura) on October 31, 2007. This transfer is based on the original joint venture agreement between Takeda and Sumitomo concluded in October 2002 for establishment of SCTA.
  • XOMA and Takeda Expand Collaboration for Therapeutic Antibody Discovery and Development February 28, 2007
  • Berkeley, CA, and Osaka, JAPAN - February 28, 2007 - XOMA Ltd. (Nasdaq: XOMA) and Takeda Pharmaceutical Company Limited (TSE4502:Takeda) announced today they have amended their existing agreement to increase the number of potential therapeutic antibody programs under the collaboration initiated in November of 2006.With this expansion, XOMA estimates the aggregate upfront, R&D funding, milestone and other payments could exceed $230 million before royalties over the life of the agreement. Since entering the original agreement four months ago, XOMA has receivedor is otherwise due approximately $8 million as various collaboration-related payments.
  • Transfer of Shares of Mitsui Takeda Chemicals, Inc. from Takeda to Mitsui Chemicals April 3, 2006
  • Osaka, Japan, --- Takeda Pharmaceutical Company Limited ("Takeda", President & COO : Yasuchika Hasegawa) announced today that all of Takeda's shares of Mitsui Takeda Chemicals Inc. ("MTCI", President: Masafumi Kataita) had been transferred to Mitsui Chemicals, Inc. ("MCI", President: Kenji Fujiyoshi) on April 1. Upon transfer of shares, MTCI changed its name to Mitsui Chemicals Polyurethanes, Inc.

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next

Page Top